Clinical trial report of treating E. coli. infected chicken by Changliqing decoction

E. colibacillosis is considered to be one of the major bacterial diseases in the poultry industry. In this study, E. colibacillosis was induced by artificial infection in chicken and cured by Changliqing decoction, thus to verify the therapeutic effect via clinical trials. Several factors, including clinical symptoms, mortality rate, hatching performance, autopsy changes, were monitored and analyzed. Data showed that compared with positive control, the mortality rate were dramatically lower, indicating a significance of difference (P<;0.05), but are dosage independent. Furthermore, high and medium dosage groups of Changliqing decoction treated chicken showed remarkably higher rate on daily gain against both positive control and positive drug control (P<;0.05). Additionally, by analyzing the clinical symptoms and autopsy changes, there is no significant difference (P>;0.05) between the control group and Changliqing decoction treated groups (dosage irrelevant). All above results indicates that Changliqing decoction treatment potentially performs positive for curing E. colibacillosis on clinical level and recommended dosage is about 1.5 ml/kg once a day.